Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven, Leuven, Belgium; Department of Urology, Airlangga University School of Medicine, Dr Soetomo General Hospital, Surabaya, Indonesia.
Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Sex Med Rev. 2017 Apr;5(2):222-235. doi: 10.1016/j.sxmr.2016.11.002. Epub 2016 Dec 29.
Stem cells for sexual disorders are steadily being introduced into clinical trials. Two conditions of importance are the main target for this line of treatment, especially when regarding the wide array of translational and basic science highlighting the potential advantages of regenerative therapy: erectile dysfunction (ED) and more recently Peyronie disease (PD). Cellular therapy offers a treatment modality that might reverse disease progression. It would be used in a curative setting, in contrast to other pharmaceutical agents that are currently available.
To review basic preclinical studies and recent clinical trials of stem cells on ED and PD.
A search of the medical literature for the following terms was performed using PubMed: stem cells, cellular therapy, erectile dysfunction, Peyronie's disease, and clinical trial.
A non-systematic narrative review and critical reflection on preclinical and clinical studies administering stem cells for ED and PD in animal models and human subjects.
Numerous studies have confirmed the beneficial functional effects of stem cell injection in established animal models on ED and PD. Various stem cell types have been adopted, from embryonic to adult mesenchymal cell types. Each cell type offers distinctive advantages and disadvantages. Diverse administrations of stem cells were investigated, with insignificant variability in the ultimate results. Stem cells appear to have a pronounced paracrine effect, rather than the classic engraftment and differentiation hypothesis. Phase 1 clinical trials using stem cells have not reported any severe adverse events in animals. However, these results cannot be extrapolated to draw any conclusions about efficacy in human patients.
Stem cells have an established efficacy in preclinical studies and early clinical trials. Studies are currently being published demonstrating the safety of intrapenile injection of autologous bone marrow- and adipose tissue-derived stem cells. Soebadi MA, Milenkovic U, Weyne E, et al. Stem Cells in Male Sexual Dysfunction: Are We Getting Somewhere? Sex Med Rev 2017;5:222-235.
用于治疗性功能障碍的干细胞正在逐步被引入临床试验。有两种情况是这种治疗方法的主要目标，特别是当涉及到广泛的转化和基础科学研究，强调再生疗法的潜在优势时：勃起功能障碍（ED）和最近的佩罗尼病（PD）。细胞疗法提供了一种可能逆转疾病进展的治疗方法。它将被用于治疗疾病，与目前可用的其他药物治疗方法形成对比。
综述干细胞治疗 ED 和 PD 的基础临床前研究和最近的临床试验。
使用 PubMed 对以下术语进行了医学文献搜索：干细胞、细胞疗法、勃起功能障碍、佩罗尼病和临床试验。
对动物模型和人类受试者中干细胞治疗 ED 和 PD 的临床前和临床研究进行非系统性叙述性综述和批判性思考。
大量研究证实了干细胞注射在 ED 和 PD 动物模型中的有益功能作用。已经采用了各种干细胞类型，从胚胎到成体间充质细胞类型。每种细胞类型都有独特的优缺点。不同的干细胞给药方式进行了研究，但最终结果没有显著差异。干细胞似乎具有明显的旁分泌作用，而不是经典的植入和分化假说。使用干细胞的 1 期临床试验在动物中没有报告任何严重的不良事件。然而，这些结果不能外推到人类患者中得出任何关于疗效的结论。
干细胞在临床前研究和早期临床试验中具有既定的疗效。目前正在发表的研究表明，自体骨髓和脂肪组织来源的干细胞阴茎内注射是安全的。Soebadi MA，Milenkovic U，Weyne E，等。男性性功能障碍中的干细胞：我们是否有所进展？性医学评论 2017；5：222-235。
